Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
DBV submitted a biologics license application to the FDA for its Viaskin Peanut patch for children aged four to seven. Portzamparc said the milestone follows a failed 2020 application for the 4-11 age group and that the redesigned patch and stronger clinical data support the new submission; DBV requested priority revie
DBV Technologies SA said it submitted a Biologics License Application to the U.S. FDA for its Viaskin® peanut patch in children aged 4-7, requesting priority review.
DBV Technologies SA EURONEXT:DBV
DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review; the FDA previously granted Breakthrough Therapy designation.